SCHEMBL84648

SCHEMBL84648

CNc1ccncn1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29608372 1.00
Hydrochloric Acid SCHEMBL2752888 0.98 CYP1A2 (0.44)
Malonic Acid SCHEMBL10505867 0.84 P2RX7 (0.43)
SCHEMBL4630887 0.79 GSK3A (0.53)
Hydrochloric Acid SCHEMBL7857018 0.77 GSK3A (0.51)
SCHEMBL30488472 0.75
SCHEMBL7854417 0.75
SCHEMBL26698946 0.75
SCHEMBL311748 0.75
SCHEMBL2086404 0.75

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 245 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110669058-A Tricyclic quinolone carboxylic acid and preparation method thereof 江西农业大学 2020-01-10 CN claimed
US-20140128373-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PLEXXIKON INC. 2014-05-08 US claimed
US-8680275-B2 Fused heterocyclic compounds as orexin receptor modulators JANSSEN PHARMACEUTICA NV (BE) 2014-03-25 US claimed
EP-2672967-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR Plexxikon, Inc. (US) 2013-12-18 EP claimed
EP-2491034-B1 FUSED HETEROCYCLIC COMPOUNDS AS OREXIN RECEPTOR MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2013-12-18 EP claimed
WO-2012109075-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PLEXXIKON INC. (US) 2012-08-16 WO claimed
US-20120202783-A1 FUSED HETEROCYCLIC COMPOUNDS AS OREXIN RECEPTOR MODULATORS JANSSEN RESEARCH NV (BE) 2012-08-09 US claimed
CN-1767888-B Process for separating fluid components from a fluid mixture by adsorption using microchannel process technology VELOCYS INC 2010-11-03 CN claimed
CN-1767888-A Process for separating fluid components from a fluid mixture by adsorption using microchannel process technology VELOCYS INC (US) 2006-05-03 CN claimed
EP-0873317-A1 PYRIMIDIN DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 1998-10-28 EP claimed
WO-1997013759-A1 PYRIMIDIN DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 1997-04-17 WO claimed
US-12240836-B2 Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof DONG-A ST CO., LTD. (KR) 2025-03-04 US disclosed
US-20240072809-A1 ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS AVILAR THERAPEUTICS, INC. (US) 2024-02-29 US disclosed
US-20240025884-A1 COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF DONG-A ST CO., LTD. (KR) 2024-01-25 US disclosed
WO-2023245166-A2 COMPOUNDS FOR TREATMENT OF A CORONAVIRUS INFECTION TRAWSFYNYDD THERAPEUTICS, INC. (US) 2023-12-21 WO disclosed
US-20030031704-A1 Liposome mixture of a lipid that is neutral in charge at physiologic pH and positively charged at pH values less than physiological pH, and a lipid joined to a hydrophilic polymer by an aromatic disulfide linkage, associated with a nucleic ALZA CORPORATION 2003-02-13 US disclosed
WO-2002096390-A1 NEUTRAL-CATIONIC LIPID FOR SYSTEMIC DELIVERY OF FACTOR VIII GENE ALZA CORPORATION (US) 2002-12-05 WO disclosed
CN-1318051-A Novel urea derivative having aromatic nitrogen-containing heterocycle SANTEN PHARMACEUTICAL CO LTD (JP) 2001-10-17 CN disclosed
US-4416885-A MUSCULAR DISORDERS SOCIETE D'ETUDES DE PRODUITS CHIMIQUES (FR) 1983-11-22 US disclosed
US-3969101-A 4,6-DIAMINO-5-NITRO-2-ALKYLTHIO-PYRIMIDINES CIBA-GEIGY CORPORATION (US) 1976-07-13 US disclosed